The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reached all time high today, Dec, 8 and still has $236.65 target or 6.00% above today’s $223.25 share price. This indicates more upside for the $57.41 billion company. This technical setup was reported by Barchart.com. If the $236.65 PT is reached, the company will be worth $3.44 billion more. The stock increased 0.08% or $0.18 during the last trading session, reaching $223.25. About 860,480 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has declined 4.47% since December 8, 2018 and is downtrending. It has underperformed by 4.47% the S&P500. Some Historical VRTX News: 04/04/2018 – Q-State Biosciences and Vertex Pharmaceuticals Enter into Multi-Year Drug Discovery Collaboration; 02/05/2018 – Vertex Releases Integration with Magento Commerce; 26/04/2018 – VERTEX 1Q ADJ EPS 76C, EST. 62C; 04/04/2018 – Q-STATE BIOSCIENCES – PER TERMS OF DEAL, CO TO RECEIVE UPFRONT & RESEARCH SUPPORT, ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT & SALES MILESTONES; 30/05/2018 – S&PGR Rates Vertex Aerospace Services ‘B’, Pos Outlook; 26/04/2018 – Vertex Pharmaceuticals Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People With Cystic Fibrosis; 19/03/2018 – VERTEX RESOURCE GROUP – ANTICIPATES PRICING AND MARGIN OF ITS SERVICES TO IMPROVE SLIGHTLY IN 2018; 09/04/2018 – VERIFONE SYSTEMS – VERTEX HOLDCO TO BE REQUIRED TO PAY FEE OF $186.6 MLN IF MERGER AGREEMENT IS TERMINATED UNDER CERTAIN CIRCUMSTANCES – SEC FILING; 13/04/2018 – CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018; 26/04/2018 – VERTEX PHARMACEUTICALS INC QTRLY ADJ SHR $0.76
Blue Martini Software Inc (BLUE) investors sentiment decreased to 0.81 in Q3 2019. It’s down -0.46, from 1.27 in 2019Q2. The ratio worsened, as 83 hedge funds increased or opened new positions, while 102 sold and reduced their positions in Blue Martini Software Inc. The hedge funds in our database now own: 61.82 million shares, up from 60.47 million shares in 2019Q2. Also, the number of hedge funds holding Blue Martini Software Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 39 Reduced: 63 Increased: 62 New Position: 21.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. The company has market cap of $4.40 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. It currently has negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.
The stock decreased 1.53% or $1.23 during the last trading session, reaching $79.42. About 1.03M shares traded or 8.04% up from the average. bluebird bio, Inc. (BLUE) has declined 15.47% since December 8, 2018 and is downtrending. It has underperformed by 15.47% the S&P500. Some Historical BLUE News: 17/04/2018 – Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma; 13/03/2018 – GENSCRIPT BIOTECH -UNIT RECEIVED PERMISSION OF CLINICAL TRIAL GRANTED BY CHINA FDA WITH RESPECT TO LCAR- B38M CAR-T FOR AUTOLOGOUS INFUSION; 20/04/2018 – STAT Plus: NIH is sued for plans to award exclusive license for CAR-T therapy to Gilead; 23/05/2018 – BLUEBIRD BIO: FDA GRANTS BREAKTHROUGH DESIGNATION TO LENTI-D; 26/04/2018 – Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World O; 30/05/2018 – Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma; 13/04/2018 – CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018; 18/04/2018 – bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia; 16/05/2018 – bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy; 28/03/2018 – bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on February, 20. They expect $-3.79 EPS, down 39.34% or $1.07 from last year’s $-2.72 per share. After $-3.73 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts 1.61% negative EPS growth.
Healthcor Management L.P. holds 1.76% of its portfolio in bluebird bio, Inc. for 507,090 shares. Dafna Capital Management Llc owns 25,500 shares or 0.88% of their US portfolio. Moreover, Sands Capital Management Llc has 0.64% invested in the company for 2.18 million shares. The Sweden-based Rhenman & Partners Asset Management Ab has invested 0.6% in the stock. Tekla Capital Management Llc, a Massachusetts-based fund reported 140,286 shares.
More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Nasdaq.com which released: “Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock? – Nasdaq” on December 03, 2019, also Seekingalpha.com with their article: “Bluebird bio’s LentiGlobin gene therapy shows significant effect in SCD study – Seeking Alpha” published on December 07, 2019, Nasdaq.com published: “Jeff Bezos’ Blue Origin Beats Air Force in Court — but Does It Matter? – Nasdaq” on December 03, 2019. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Nasdaq.com and their article: “4 Top Stock Trades for Monday: GS, BIG, BMY – Nasdaq” published on December 06, 2019 as well as Nasdaq.com‘s news article titled: “5 Blue Chip Stocks to Buy on the Dip for a Stronger Portfolio – Nasdaq” with publication date: December 06, 2019.
Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $57.41 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 27.09 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.
More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Finance.Yahoo.com which released: “Hedge Funds Are Warming Up To Vertex Pharmaceuticals Incorporated (VRTX) – Yahoo Finance” on November 28, 2019, also Nasdaq.com with their article: “Earnings Estimates Rising for Vertex (VRTX): Will It Gain? – Nasdaq” published on November 15, 2019, Nasdaq.com published: “Drug Approvals, Upbeat Earnings Help Vertex Pharmaceuticals’ Stock Jump 20% In A Month – Nasdaq” on November 19, 2019. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Nasdaq.com and their article: “Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi – Nasdaq” published on November 21, 2019 as well as Nasdaq.com‘s news article titled: “Here’s Why Vertex Pharmaceuticals Rose 13.4% in November – Nasdaq” with publication date: December 04, 2019.
Among 16 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 15 have Buy rating, 0 Sell and 1 Hold. Therefore 94% are positive. Vertex Pharmaceuticals has $25400 highest and $203 lowest target. $229.56’s average target is 2.83% above currents $223.25 stock price. Vertex Pharmaceuticals had 30 analyst reports since August 1, 2019 according to SRatingsIntel. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Hold” rating given on Tuesday, October 22 by Leerink Swann. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, October 31. The rating was maintained by J.P. Morgan with “Buy” on Monday, October 21. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Overweight” rating given on Thursday, October 31 by Morgan Stanley. The stock has “Buy” rating by Robert W. Baird on Monday, October 21. Credit Suisse maintained the stock with “Buy” rating in Tuesday, October 22 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Stifel Nicolaus on Thursday, August 1. Jefferies maintained it with “Buy” rating and $220 target in Monday, October 21 report. On Friday, September 6 the stock rating was maintained by Morgan Stanley with “Overweight”. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, October 31 report.
Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on February, 4. They expect $0.95 earnings per share, down 5.00% or $0.05 from last year’s $1 per share. VRTX’s profit will be $244.29M for 58.75 P/E if the $0.95 EPS becomes a reality. After $0.97 actual earnings per share reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -2.06% negative EPS growth.
Investors sentiment increased to 1.31 in Q3 2019. Its up 0.14, from 1.17 in 2019Q2. It is positive, as 37 investors sold Vertex Pharmaceuticals Incorporated shares while 166 reduced holdings. 62 funds opened positions while 204 raised stakes. 234.70 million shares or 0.28% less from 235.36 million shares in 2019Q2 were reported. Axa owns 290,959 shares. Dana Invest Advisors accumulated 14,259 shares. Pitcairn reported 0.03% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Franklin has 1.25 million shares. Amalgamated Comml Bank reported 0.15% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Massmutual Fsb Adv reported 14,368 shares. Dakota Wealth has 0.06% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2,000 shares. Daiwa Secs Group Inc Incorporated accumulated 12,428 shares. Ingalls & Snyder Ltd Liability reported 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Moreover, Meiji Yasuda Life Ins has 0.16% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Bnp Paribas Arbitrage has invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Ballentine Prtnrs Limited Liability Company stated it has 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Utah Retirement System stated it has 48,739 shares or 0.16% of all its holdings. Amp Cap Invsts Ltd stated it has 0.08% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Canada Pension Plan Investment Board holds 365,820 shares.